Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells

Kewa Gao, Priyadarsini Kumar, Elizabeth Cortez-Toledo, Dake Hao, Lizette Reynaga, Melanie Rose, Chuwang Wang, Diana L Farmer, Jan Nolta, Jianda Zhou, Ping Zhou, Aijun Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the Factor VIII (FVIII) gene leading to deficient blood coagulation. As a monogenic disorder, HA is an ideal target for cell-based gene therapy, but successful treatment has been hampered by insufficient engraftment of potential therapeutic cells. Methods: In this study, we sought to determine whether co-transplantation of endothelial colony-forming cells (ECFCs) and placenta-derived mesenchymal stromal cells (PMSCs) can achieve long-term engraftment and FVIII expression. ECFCs and PMSCs were transduced with a B domain deleted factor VIII (BDD-FVIII) expressing lentiviral vector and luciferase, green fluorescent protein or Td-Tomato containing lentiviral tracking vectors. They were transplanted intramuscularly into neonatal or adult immunodeficient mice. Results: In vivo bioluminescence imaging showed that the ECFC only and the co-transplantation groups but not the PMSCs only group achieved long-term engraftment for at least 26 weeks, and the co-transplantation group showed a higher engraftment than the ECFC only group at 16 and 20 weeks post-transplantation. In addition, cell transplantation at the neonatal age achieved higher engraftment than at the adult age. Immunohistochemical analyses further showed that the engrafted ECFCs expressed FVIII, maintained endothelial phenotype, and generated functional vasculature. Next, co-transplantation of ECFCs and PMSCs into F8 knock-out HA mice reduced the blood loss volume from 562.13 ± 19.84 μl to 155.78 ± 44.93 μl in a tail-clip assay. Conclusions: This work demonstrated that co-transplantation of ECFCs with PMSCs at the neonatal age is a potential strategy to achieve stable, long-term engraftment, and thus holds great promise for cell-based treatment of HA.

Original languageEnglish (US)
Article number34
JournalStem Cell Research and Therapy
Volume10
Issue number1
DOIs
StatePublished - Jan 22 2019

Fingerprint

Factor VIII
Hemophilia A
Mesenchymal Stromal Cells
Fetal Blood
Blood
Transplantation
Placenta
Bioluminescence
Gene therapy
Green Fluorescent Proteins
Coagulation
Luciferases
Assays
Therapeutics
Genes
Imaging techniques
Cell Transplantation
Blood Coagulation
Lycopersicon esculentum
Blood Volume

Keywords

  • Cell engraftment
  • Co-transplantation
  • Endothelial colony-forming cells (ECFCs)
  • Hemophilia A
  • Mesenchymal stromal cells (MSCs)
  • Neonatal

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology

Cite this

Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells. / Gao, Kewa; Kumar, Priyadarsini; Cortez-Toledo, Elizabeth; Hao, Dake; Reynaga, Lizette; Rose, Melanie; Wang, Chuwang; Farmer, Diana L; Nolta, Jan; Zhou, Jianda; Zhou, Ping; Wang, Aijun.

In: Stem Cell Research and Therapy, Vol. 10, No. 1, 34, 22.01.2019.

Research output: Contribution to journalArticle

@article{6ad28d4d75ca4cea93e7aebc982eb950,
title = "Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells",
abstract = "Background: Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the Factor VIII (FVIII) gene leading to deficient blood coagulation. As a monogenic disorder, HA is an ideal target for cell-based gene therapy, but successful treatment has been hampered by insufficient engraftment of potential therapeutic cells. Methods: In this study, we sought to determine whether co-transplantation of endothelial colony-forming cells (ECFCs) and placenta-derived mesenchymal stromal cells (PMSCs) can achieve long-term engraftment and FVIII expression. ECFCs and PMSCs were transduced with a B domain deleted factor VIII (BDD-FVIII) expressing lentiviral vector and luciferase, green fluorescent protein or Td-Tomato containing lentiviral tracking vectors. They were transplanted intramuscularly into neonatal or adult immunodeficient mice. Results: In vivo bioluminescence imaging showed that the ECFC only and the co-transplantation groups but not the PMSCs only group achieved long-term engraftment for at least 26 weeks, and the co-transplantation group showed a higher engraftment than the ECFC only group at 16 and 20 weeks post-transplantation. In addition, cell transplantation at the neonatal age achieved higher engraftment than at the adult age. Immunohistochemical analyses further showed that the engrafted ECFCs expressed FVIII, maintained endothelial phenotype, and generated functional vasculature. Next, co-transplantation of ECFCs and PMSCs into F8 knock-out HA mice reduced the blood loss volume from 562.13 ± 19.84 μl to 155.78 ± 44.93 μl in a tail-clip assay. Conclusions: This work demonstrated that co-transplantation of ECFCs with PMSCs at the neonatal age is a potential strategy to achieve stable, long-term engraftment, and thus holds great promise for cell-based treatment of HA.",
keywords = "Cell engraftment, Co-transplantation, Endothelial colony-forming cells (ECFCs), Hemophilia A, Mesenchymal stromal cells (MSCs), Neonatal",
author = "Kewa Gao and Priyadarsini Kumar and Elizabeth Cortez-Toledo and Dake Hao and Lizette Reynaga and Melanie Rose and Chuwang Wang and Farmer, {Diana L} and Jan Nolta and Jianda Zhou and Ping Zhou and Aijun Wang",
year = "2019",
month = "1",
day = "22",
doi = "10.1186/s13287-019-1138-8",
language = "English (US)",
volume = "10",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells

AU - Gao, Kewa

AU - Kumar, Priyadarsini

AU - Cortez-Toledo, Elizabeth

AU - Hao, Dake

AU - Reynaga, Lizette

AU - Rose, Melanie

AU - Wang, Chuwang

AU - Farmer, Diana L

AU - Nolta, Jan

AU - Zhou, Jianda

AU - Zhou, Ping

AU - Wang, Aijun

PY - 2019/1/22

Y1 - 2019/1/22

N2 - Background: Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the Factor VIII (FVIII) gene leading to deficient blood coagulation. As a monogenic disorder, HA is an ideal target for cell-based gene therapy, but successful treatment has been hampered by insufficient engraftment of potential therapeutic cells. Methods: In this study, we sought to determine whether co-transplantation of endothelial colony-forming cells (ECFCs) and placenta-derived mesenchymal stromal cells (PMSCs) can achieve long-term engraftment and FVIII expression. ECFCs and PMSCs were transduced with a B domain deleted factor VIII (BDD-FVIII) expressing lentiviral vector and luciferase, green fluorescent protein or Td-Tomato containing lentiviral tracking vectors. They were transplanted intramuscularly into neonatal or adult immunodeficient mice. Results: In vivo bioluminescence imaging showed that the ECFC only and the co-transplantation groups but not the PMSCs only group achieved long-term engraftment for at least 26 weeks, and the co-transplantation group showed a higher engraftment than the ECFC only group at 16 and 20 weeks post-transplantation. In addition, cell transplantation at the neonatal age achieved higher engraftment than at the adult age. Immunohistochemical analyses further showed that the engrafted ECFCs expressed FVIII, maintained endothelial phenotype, and generated functional vasculature. Next, co-transplantation of ECFCs and PMSCs into F8 knock-out HA mice reduced the blood loss volume from 562.13 ± 19.84 μl to 155.78 ± 44.93 μl in a tail-clip assay. Conclusions: This work demonstrated that co-transplantation of ECFCs with PMSCs at the neonatal age is a potential strategy to achieve stable, long-term engraftment, and thus holds great promise for cell-based treatment of HA.

AB - Background: Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the Factor VIII (FVIII) gene leading to deficient blood coagulation. As a monogenic disorder, HA is an ideal target for cell-based gene therapy, but successful treatment has been hampered by insufficient engraftment of potential therapeutic cells. Methods: In this study, we sought to determine whether co-transplantation of endothelial colony-forming cells (ECFCs) and placenta-derived mesenchymal stromal cells (PMSCs) can achieve long-term engraftment and FVIII expression. ECFCs and PMSCs were transduced with a B domain deleted factor VIII (BDD-FVIII) expressing lentiviral vector and luciferase, green fluorescent protein or Td-Tomato containing lentiviral tracking vectors. They were transplanted intramuscularly into neonatal or adult immunodeficient mice. Results: In vivo bioluminescence imaging showed that the ECFC only and the co-transplantation groups but not the PMSCs only group achieved long-term engraftment for at least 26 weeks, and the co-transplantation group showed a higher engraftment than the ECFC only group at 16 and 20 weeks post-transplantation. In addition, cell transplantation at the neonatal age achieved higher engraftment than at the adult age. Immunohistochemical analyses further showed that the engrafted ECFCs expressed FVIII, maintained endothelial phenotype, and generated functional vasculature. Next, co-transplantation of ECFCs and PMSCs into F8 knock-out HA mice reduced the blood loss volume from 562.13 ± 19.84 μl to 155.78 ± 44.93 μl in a tail-clip assay. Conclusions: This work demonstrated that co-transplantation of ECFCs with PMSCs at the neonatal age is a potential strategy to achieve stable, long-term engraftment, and thus holds great promise for cell-based treatment of HA.

KW - Cell engraftment

KW - Co-transplantation

KW - Endothelial colony-forming cells (ECFCs)

KW - Hemophilia A

KW - Mesenchymal stromal cells (MSCs)

KW - Neonatal

UR - http://www.scopus.com/inward/record.url?scp=85060378547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060378547&partnerID=8YFLogxK

U2 - 10.1186/s13287-019-1138-8

DO - 10.1186/s13287-019-1138-8

M3 - Article

C2 - 30670078

AN - SCOPUS:85060378547

VL - 10

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - 1

M1 - 34

ER -